0000950170-24-080723.txt : 20240702
0000950170-24-080723.hdr.sgml : 20240702
20240702171717
ACCESSION NUMBER: 0000950170-24-080723
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240628
FILED AS OF DATE: 20240702
DATE AS OF CHANGE: 20240702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Casdin Eli
CENTRAL INDEX KEY: 0001534264
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34180
FILM NUMBER: 241097026
MAIL ADDRESS:
STREET 1: 1350 AVENUE OF THE AMERICAS
STREET 2: SUITE 1140
CITY: NEW YORK
STATE: NY
ZIP: 10019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: STANDARD BIOTOOLS INC.
CENTRAL INDEX KEY: 0001162194
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 770513190
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 TOWER PLACE
STREET 2: SUITE 2000
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6502666000
MAIL ADDRESS:
STREET 1: 2 TOWER PLACE
STREET 2: SUITE 2000
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: FLUIDIGM CORP
DATE OF NAME CHANGE: 20011113
4
1
ownership.xml
4
X0508
4
2024-06-28
0001162194
STANDARD BIOTOOLS INC.
LAB
0001534264
Casdin Eli
C/O STANDARD BIOTOOLS INC.
2 TOWER PLACE, STE 2000
SOUTH SAN FRANCISCO
CA
94080
true
false
true
false
false
Common Stock
2024-06-28
4
A
false
43128
0
A
2750744
D
Common Stock
13939637
I
Casdin Private Growth Equity Fund II, L.P.
Common Stock
2744219
I
By Casdin Private Growth Equity Fund, L.P.
Common Stock
18870
I
See footnote
Common Stock
46730821
I
Casdin Partners Master Fund, L.P
Common Stock
545000
I
Casdin Amplify Fund, LP
Stock Option (Right to buy)
1.77
2024-06-28
4
A
false
72213
0
A
2034-06-28
Common Stock
72213
72213
D
Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 28, 2025 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
Includes 2,604,060 shares of common stock received in a pro rata distribution for no consideration by C-LSH II LLC in accordance with the exemptions afforded by Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
The securities are indirectly owned by Eli Casdin who has voting and investment discretion with respect to the securities.
The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
The securities are owned directly by Casdin Amplify Fund, LP ("Amplify") and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin and the GP.
The Option becomes exercisable in twelve equal monthly installments beginning on July 28, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
The Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
/s/ Eli Casdin by Agnieszka Gallagher, Attorney-in-Fact
2024-07-02